The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
Authors
Keywords
-
Journal
Diabetes Therapy
Volume 11, Issue 4, Pages 835-844
Publisher
Springer Science and Business Media LLC
Online
2020-03-17
DOI
10.1007/s13300-020-00798-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial
- (2019) Vlado Perkovic et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial
- (2019) M. Angelyn Bethel et al. DIABETES CARE
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2019) Søren L Kristensen et al. Lancet Diabetes & Endocrinology
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
- (2018) Katherine R Tuttle et al. Lancet Diabetes & Endocrinology
- Glucagon-Like Peptide-1 and its Cleavage Products are Renoprotective in Murine Diabetic Nephropathy
- (2018) Moellmann Julia et al. DIABETES
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
- (2018) Marcel H A Muskiet et al. Lancet Diabetes & Endocrinology
- GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
- (2017) Marcel H. A. Muskiet et al. Nature Reviews Nephrology
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- GLP-1 agonist associated acute kidney injury: A case report and review
- (2017) T. Sharma et al. DIABETES & METABOLISM
- Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial
- (2016) J. Skov et al. DIABETES OBESITY & METABOLISM
- Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial
- (2016) Lennart Tonneijck et al. DIABETOLOGIA
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats
- (2015) Xiaoyan Zhou et al. Cardiovascular Diabetology
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
- (2014) Charles Pyke et al. ENDOCRINOLOGY
- Acute Interstitial Nephritis After Treatment With Liraglutide
- (2013) Karim Gariani et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Severe acute renal failure in patients treated with glucagon-like peptide-1 receptor agonists
- (2013) D. Dubois-Laforgue et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction
- (2013) Yen-Ta Chen et al. Journal of Translational Medicine
- The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential
- (2013) Hiroki Fujita et al. KIDNEY INTERNATIONAL
- A Decade After the KDOQI CKD Guidelines: Impact on the National Kidney Foundation
- (2012) Joseph A. Vassalotti et al. AMERICAN JOURNAL OF KIDNEY DISEASES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started